These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 7981064)

  • 1. The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody.
    Pedley RB; Boden JA; Boden R; Begent RH; Turner A; Haines AM; King DJ
    Br J Cancer; 1994 Dec; 70(6):1126-30. PubMed ID: 7981064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification.
    Delgado C; Pedley RB; Herraez A; Boden R; Boden JA; Keep PA; Chester KA; Fisher D; Begent RH; Francis GE
    Br J Cancer; 1996 Jan; 73(2):175-82. PubMed ID: 8546903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model.
    Pedley RB; Boden JA; Boden R; Dale R; Begent RH
    Br J Cancer; 1993 Jul; 68(1):69-73. PubMed ID: 8318423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments.
    Casey JL; King DJ; Chaplin LC; Haines AM; Pedley RB; Mountain A; Yarranton GT; Begent RH
    Br J Cancer; 1996 Nov; 74(9):1397-405. PubMed ID: 8912535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts.
    Vogel CA; Bischof-Delaloye A; Mach JP; Pèlegrin A; Hardman N; Delaloye B; Buchegger F
    Br J Cancer; 1993 Oct; 68(4):684-90. PubMed ID: 8398694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative tumour localization of antibody fragments and intact IgG in nude mice bearing a CEA-producing human colon tumour xenograft.
    Harwood PJ; Boden J; Pedley RB; Rawlins G; Rogers GT; Bagshawe KD
    Eur J Cancer Clin Oncol; 1985 Dec; 21(12):1515-22. PubMed ID: 3830730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Significance of circulatory clearance of tumour-localising IgG and F(ab')2 for potential therapy studied in a CEA-producing xenograft model.
    Harwood PJ; Pedley RB; Boden J; Rogers GT
    Tumour Biol; 1987; 8(1):19-25. PubMed ID: 3602844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.
    Marshall D; Pedley RB; Melton RG; Boden JA; Boden R; Begent RH
    Br J Cancer; 1995 Jan; 71(1):18-24. PubMed ID: 7529526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting of human breast cancer by a bispecific antibody directed against two tumour-associated antigens: ErbB-2 and carcinoembryonic antigen.
    Dorvillius M; Garambois V; Pourquier D; Gutowski M; Rouanet P; Mani JC; Pugnière M; Hynes NE; Pèlegrin A
    Tumour Biol; 2002; 23(6):337-47. PubMed ID: 12677091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiolocalisation of an anti-CEA monoclonal antibody (FO23C5) and its fragments in a colon carcinoma xenograft model.
    Rowlinson G; Paganelli G; Snook D; Epenetos AA
    Int J Biol Markers; 1988; 3(4):259-64. PubMed ID: 3235854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Localisation of monoclonal antibodies reacting with different epitopes on carcinoembryonic antigen (CEA)--implications for targeted therapy.
    Boxer GM; Abassi AM; Pedley RB; Begent RH
    Br J Cancer; 1994 Feb; 69(2):307-14. PubMed ID: 7507692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Altered biodistribution of an antibody--enzyme conjugate modified with polyethylene glycol.
    Eno-Amooquaye EA; Searle F; Boden JA; Sharma SK; Burke PJ
    Br J Cancer; 1996 Jun; 73(11):1323-7. PubMed ID: 8645574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of unlabelled monoclonal antibodies on the biodistribution of 111In-labelled anti-prostate-specific acid phosphatase monoclonal antibodies in the mouse model.
    Peräalä-Heape M; Vihko P; Vihko R
    Anticancer Res; 1991; 11(3):1327-31. PubMed ID: 1888168
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polyethylene glycol modification of the monoclonal antibody A7 enhances its tumor localization.
    Kitamura K; Takahashi T; Takashina K; Yamaguchi T; Noguchi A; Tsurumi H; Toyokuni T; Hakomori S
    Biochem Biophys Res Commun; 1990 Sep; 171(3):1387-94. PubMed ID: 2222451
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered pharmacokinetic and tumour localization properties of Fab' fragments of a murine monoclonal anti-CEA antibody by covalent modification with low molecular weight dextran.
    Fagnani R; Halpern S; Hagan M
    Nucl Med Commun; 1995 May; 16(5):362-9. PubMed ID: 7544884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
    Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
    Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
    Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts.
    Deckert PM; Jungbluth A; Montalto N; Clark MA; Finn RD; Williams C; Richards EC; Panageas KS; Old LJ; Welt S
    Int J Cancer; 2000 Aug; 87(3):382-90. PubMed ID: 10897044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose-dependent localisation and potential for therapy of F(ab')2 fragments against CEA studied in a human tumour xenograft model.
    Rogers GT; Harwood PJ; Pedley RB; Boden J; Bagshawe KD
    Br J Cancer; 1986 Aug; 54(2):341-4. PubMed ID: 3741770
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.